Star Anise, Shikimic Acid and Antiviral Research

Table of Contents

1. The Myth, Stated Precisely
2. Where Shikimic Acid Comes From
3. Why Star Anise Specifically
4. From Shikimic Acid to Oseltamivir: the Actual Chemistry
5. How Oseltamivir Works, and Why the Plant Cannot
6. The 2005 and 2009 Supply Panics
7. How Fermentation Offers a Route Without the Harvest
8. The Real Antiviral Research on Illicium verum
9. What Oseltamivir Itself Actually Achieves
10. Marketing Claims and What the Evidence Shows
11. What the Research Reports for Influenza
12. Key Research Papers
13. Connections
14. Featured Videos

The Myth, Stated Precisely

The reasoning runs like this, and each numbered step is worth labelling:

1. Oseltamivir is made from star anise. — Roughly true, historically. Oseltamivir was manufactured from shikimic acid, and shikimic acid was extracted from Illicium verum fruit.
2. Therefore star anise contains the active ingredient of oseltamivir. — False. It contains a feedstock, not the drug.
3. Therefore star anise tea has antiviral activity against influenza. — False, and does not follow even if step 2 were granted.
4. Therefore star anise tea can prevent or treat flu. — False, unsupported by any human evidence, and potentially harmful through delay.

The break happens at step 2, and it is a category error about what a starting material is. Two analogies make it stick because they are structurally identical:

• Sand is the starting material for computer chips. Eating sand does not give you a laptop. Silicon is in both; the transistor is not in the sand.
• Crude oil is a starting material for paracetamol. Drinking crude oil does not relieve a headache. Carbon and hydrogen are in both; the analgesic molecule is not in the oil.

A third analogy is closer to the chemistry: wheat flour is a starting material for bread, but eating flour is not eating bread, and no amount of flour in your stomach performs the kneading, proving and baking. Chemical synthesis is a manufacturing process, not a digestion process.

Where Shikimic Acid Comes From

Shikimic acid is not exotic. It is a normal intermediate in the shikimate pathway, the biosynthetic route that plants, fungi, bacteria and apicomplexan parasites use to build the aromatic amino acids phenylalanine, tyrosine and tryptophan — and from those, an enormous share of plant secondary metabolism: lignin, tannins, flavonoids, salicylates and the phenylpropanoids that give spices their smell, star anise's own anethole included.

Two consequences follow, and both puncture the mystique.

First, animals do not have this pathway. That is precisely why phenylalanine and tryptophan are essential amino acids for humans — we cannot make them and must eat them. It is also why the shikimate pathway is such an attractive target for herbicides and antimicrobials: the herbicide glyphosate works by inhibiting an enzyme in this pathway, which is why it kills plants and not, by that mechanism, people. Since humans lack the pathway entirely, we also lack any enzymatic machinery that could do anything interesting with dietary shikimic acid.

Second, shikimic acid is everywhere. It is a universal plant metabolite present in ginkgo, sweetgum, pine needles, coffee, and most fruits and vegetables at low levels. Star anise is not unique in containing it; star anise is merely unusually concentrated in it, at a few percent of dry fruit weight, which is a commercial convenience rather than a pharmacological property.

Why Star Anise Specifically

If shikimic acid is ubiquitous, why did a global pharmaceutical supply chain end up depending on a spice grown in a handful of Chinese and Vietnamese provinces? Three practical reasons, none of them medical:

1. Concentration. The seed contains between 2 and 7% shikimic acid, with one record of up to 17% on a dry basis, high enough that extraction is economic. Most plants sit orders of magnitude lower. Even so, Martínez and colleagues report about 30 kg of seed for 1 kg of shikimic acid, from a crop that needs 6 years of growth and is harvested in September and October, and, citing a 2007 patent, about 90% of the Chinese harvest going to drug production.
2. A dried, stable, already-traded commodity. Star anise arrives as hard dry fruit with a long shelf life, harvested and graded at scale by an existing agricultural industry. Nobody had to invent a supply chain.
3. Stereochemistry. This is the real reason. Shikimic acid arrives with three chiral centres already set correctly by the plant's own enzymes. Building that arrangement from scratch is expensive and wasteful; starting from a natural product that already has it is the classic chiral-pool strategy in synthetic chemistry. The plant did the hard geometric work for free.

Note what is not on that list: any antiviral property. Star anise was chosen the way a factory chooses a raw material — on yield, cost, availability and shape.

From Shikimic Acid to Oseltamivir: the Actual Chemistry

The published industrial route from shikimic acid to oseltamivir phosphate runs to something in the region of ten steps. Without turning this into an organic chemistry lecture, the transformations include:

• Protection and activation of the several hydroxyl groups so they can be manipulated selectively rather than all at once.
• Formation of an epoxide — a strained three-membered oxygen ring that serves as the reactive handle for the next stage.
• Installation of the 3-pentyloxy side chain, the bulky ether group that occupies a hydrophobic pocket in the viral enzyme. This group does not exist in shikimic acid. It comes from a petrochemical reagent.
• Introduction of two nitrogen atoms to build the amino and acetamido groups. In the original process this went through hazardous azide intermediates — azides are explosion risks at scale and process chemists worked for years to design them out. Shikimic acid contains no nitrogen whatsoever.
• Esterification and salt formation to give the ethyl ester phosphate salt that is actually swallowed.

Two things are worth extracting from that list. The finished drug contains nitrogen atoms that the starting material does not have — not rearranged, not liberated, simply absent and then added. And the side chain that gives oseltamivir its potency is a piece of deliberate medicinal-chemistry design bolted on in a reactor.

Oseltamivir is also a prodrug: the ethyl ester is inactive and must be hydrolysed by liver carboxylesterase to oseltamivir carboxylate, the actual neuraminidase inhibitor. So the chain is plant → feedstock → ten factory steps → prodrug → liver → active drug. A cup of tea enters that chain at the first arrow and stops there.

How Oseltamivir Works, and Why the Plant Cannot

Influenza virus carries a surface enzyme called neuraminidase, which cleaves sialic acid residues from host glycoproteins. Its job comes at the end of the viral life cycle: newly assembled virions are studded with haemagglutinin that sticks to sialic acid on the cell they just left, and neuraminidase snips those tethers so the new particles can escape and spread. Block neuraminidase and the progeny virus stays glued to the dying cell.

Oseltamivir carboxylate is a transition-state analogue of sialic acid: a molecule shaped to mimic the fleeting geometry the natural substrate adopts inside the enzyme's active site, but which cannot be cleaved, so it sits in the site and blocks it. The 1997 paper by Kim, Lew, Williams and colleagues in the Journal of the American Chemical Society describes exactly this — the design, synthesis and structural analysis of carbocyclic sialic acid analogues, including the discovery that a bulky lipophilic side chain could exploit a hydrophobic pocket in the enzyme and dramatically raise potency. Read that paper and the question of whether star anise is antiviral answers itself: the activity was engineered against a crystal structure.

Shikimic acid does not resemble sialic acid, does not carry the hydrophobic side chain, has no acetamido group, and does not inhibit neuraminidase. It is a cyclohexene carboxylic acid with three hydroxyls — a scaffold, not a key.

The 2005 and 2009 Supply Panics

The myth spread because the underlying news story was real and dramatic.

When H5N1 avian influenza raised fears of a pandemic in the mid-2000s, governments moved to stockpile oseltamivir, and demand for it rose faster than any drug supply chain was built for. Reporting at the time noted that a very large share of the world's star anise crop was being directed to shikimic acid extraction for drug manufacture, and that the bottleneck in oseltamivir production was agricultural. The 2009 H1N1 pandemic produced a second round of the same coverage. Both accounts were substantially accurate as supply-chain journalism.

What happened next is a case study in how a true fact mutates. “The world's star anise is going into flu medicine” became “star anise is flu medicine,” and that version travelled far better than the original because it was actionable, cheap and available in every supermarket. Spice prices in producing regions rose. Star anise supplements and “shikimic acid” products appeared. None of it was supported, and the correction never travelled as fast as the claim.

The geographic concentration that made the story compelling was also genuine and remains so: the overwhelming majority of world production comes from Guangxi and neighbouring provinces in southern China plus Lạng Sơn and adjacent provinces in northern Vietnam. A strategic pharmaceutical input depending on the weather in a few provinces was a real vulnerability, and the industry treated it as one.

How Fermentation Offers a Route Without the Harvest

The response to that vulnerability is the most genuinely interesting part of the story, and it also finishes off the myth.

Because the shikimate pathway exists in bacteria, it can be engineered. Metabolic engineers rewired Escherichia coli to overproduce shikimic acid in fermenters: knocking out the downstream enzyme that normally consumes it, boosting flux into the pathway, balancing the phosphoenolpyruvate and erythrose-4-phosphate precursor supply, and tuning cofactor regeneration. Martínez, Bolívar and Escalante's 2015 review in Frontiers in Bioengineering and Biotechnology traces this from classical strain engineering through to omics-guided optimisation. Cui and colleagues, writing in Microbial Cell Factories in 2014, describe a strain improved by chemically inducible chromosomal evolution together with cofactor engineering.

Fermentation is weather-independent, scalable in a building rather than a province, and free of the adulteration and pesticide-residue questions that come with an agricultural feedstock. Fermentation offers a route to shikimic acid that does not need the star anise harvest. The papers cited here describe it as engineering still in progress: Martínez and colleagues write that shikimic acid for oseltamivir production is extracted from Chinese star anise, and Cui and colleagues that plants cannot deliver a stable supply. No source read for this page states that manufacturers have replaced the harvest.

The Real Antiviral Research on Illicium verum

Setting the shikimic acid confusion aside entirely, is there a laboratory literature on antiviral activity of star anise extracts? Yes, a modest one, and it should be described honestly rather than used as a rescue for the myth.

Star anise extracts and isolated constituents have been tested against various viruses in cell culture, with reported activity against herpesviruses among others, and the 2020 Phytotherapy Research review by Patra, Das, Bose and colleagues gathers this material under the explicit heading of chemical compounds, antiviral properties and clinical relevance. Proposed mechanisms are generic to plant polyphenols and lipophilic volatiles: interference with viral attachment or envelope integrity, and inhibition of viral enzymes at high extract concentrations.

Evidence tier: preliminary, in vitro plus one fish study. The standard caveats apply with full force:

• Effective concentrations in cell culture are far above anything achievable in human tissue by eating or drinking the spice.
• Crude plant extracts non-specifically interfere with many biological assays; a large fraction of published in-vitro antiviral hits from plants never replicate in an animal, let alone a person.
• No human trial has tested star anise for any viral infection, for any outcome.
• Activity against a herpesvirus in a dish says nothing about influenza in a lung.

The first test in a living animal is from 2025. A water extract of star anise slowed a fish nodavirus in fish cells at 100 and 200 micrograms per milliliter, and when it was injected into Asian seabass, all the deaths were among fish given the virus alone. This says nothing about human flu, and the extract was injected, not eaten.

So the accurate summary is: there is early laboratory work, it is legitimate research, and it does not currently support any clinical claim. It also is not the source of the popular myth — the myth came from the manufacturing story, and would be equally wrong if the in-vitro literature did not exist.

What Oseltamivir Itself Actually Achieves

An underappreciated point that reframes the whole comparison: oseltamivir is not a spectacular drug. The Cochrane review by Jefferson, Jones, Doshi and colleagues — the analysis that finally worked from full clinical study reports rather than published summaries, after a long campaign for data access — found that in adults with influenza, oseltamivir shortened the time to first symptom relief by 16.8 hours, from 7 to 6.3 days on average. It had no significant effect on hospitalisation and reduced only self-reported, unverified pneumonia (risk difference 1.00%), and the reviewers write that the trials do not settle whether complications are reduced. Adverse effects were real: nausea (risk difference 3.66%) and vomiting (4.56%).

That finding cuts in two directions at once, and both belong on this page. It means the bar star anise would have to clear is not as high as people imagine. It also means influenza has no easy fix at all, so replacing a modest drug with a spice is not a trade of something for nothing — it is a trade of a small measured benefit for none. Oseltamivir's value is usually described as concentrated in people at high risk of complications and in early treatment, which is exactly the situation in which delay is most costly.

A 2024 analysis of 15 trials in 6,166 outpatients with confirmed flu sits beside that view. Oseltamivir did not significantly lower hospital admission overall (risk ratio 0.79, confidence interval 0.48 to 1.29), in older people (1.01, 0.21 to 4.90) or in those at greater risk (0.65, 0.33 to 1.28), while it raised nausea (risk ratio 1.43) and vomiting (1.83). The authors call for an adequately powered trial in a suitably high-risk population.

Marketing Claims and What the Evidence Shows

These are claims found where these products are sold:

• “Natural oseltamivir” or “nature's oseltamivir,” usually worded with the drug's brand name. There is no such thing. The phrase is the myth compressed into two words.
• Shikimic acid sold as a supplement or flu remedy. Shikimic acid is a pharmaceutical intermediate. Sold to consumers as an antiviral, it is the myth being sold back to you.
• “Contains the active ingredient in oseltamivir.” It does not. It contains a precursor of a precursor.
• “Boosts immunity against flu.” Vague, unfalsifiable, and unsupported for star anise by any human data.
• Star anise tea marketed for children during flu season. This combines an unsupported claim with the reported infant poisonings. See the safety page.
• Any claim that star anise replaces influenza vaccination. Nothing in the literature comes within reach of that.

What the Research Reports for Influenza

Since the honest answer to “does star anise treat flu” is no, the useful follow-up is what the research reports for it:

• Annual vaccination is the intervention with the largest evidence base by an enormous margin, particularly for older adults, pregnant women, young children and anyone with chronic disease.
• Antivirals started early — ideally within 48 hours of symptom onset — for people at higher risk of complications. Benefit is modest but real, and it depends on timing, which is the practical reason the tea myth causes harm.
• A second kind of flu drug: baloxavir. A single dose blocks a different viral enzyme (cap-dependent endonuclease). In otherwise healthy outpatients aged 12 to 64, symptoms eased in 53.7 hours against 80.2 hours on placebo, about the same time as oseltamivir, and virus levels fell more at day 1 than on oseltamivir. Virus variants with reduced sensitivity to it emerged in 9.7% of those treated in that trial.
• Baloxavir and spread in the household. In a 2025 trial of 1,457 people with flu and 2,681 household contacts, baloxavir taken within 48 hours lowered spread by day 5 to 9.5% from 13.4%; spread that caused symptoms (5.8% vs 7.6%) was not significantly different. The same paper notes that neuraminidase inhibitors, the class oseltamivir belongs to, have not shown sufficient evidence of preventing transmission.
• Rest, fluids and time. Uncomplicated influenza in a healthy adult resolves on its own in about a week, with cough and fatigue lingering longer.
• Paracetamol or ibuprofen for fever and aches, at label doses.
• The warning signs — breathlessness, chest pain, confusion, persistent high fever, symptoms that improve then sharply worsen (which can signal secondary bacterial pneumonia), or any concerning illness in an infant are signs hospitals treat as urgent.

And star anise? It is a spice for a pot of ginger-and-cinnamon broth, and warm salty liquid is comforting when people feel terrible. That is a genuine and sufficient reason. It is not treatment.

Key Research Papers

Citations link the paper's PubMed record where one is known and a PubMed topic search otherwise.

1. Kim CU, Lew W, Williams MA, et al. “Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.” Journal of the American Chemical Society, 1997. The paper in which oseltamivir's activity was designed against a protein structure — the single most decisive citation against the plant-equals-drug claim. PubMed PMID: 16526129
2. Martínez JA, Bolívar F, Escalante A. “Shikimic acid production in Escherichia coli: from classical metabolic engineering strategies to omics applied to improve its production.” Frontiers in Bioengineering and Biotechnology, 2015. How fermentation can supply shikimic acid without the harvest; it gives the seed and harvest figures used above. PubMed PMID: 26442259
3. Cui YY, Ling C, Zhang YY, Huang J, Liu JZ. “Production of shikimic acid from Escherichia coli through chemically inducible chromosomal evolution and cofactor metabolic engineering.” Microbial Cell Factories, 2014. A concrete engineered-strain example. PubMed PMID: 24512078
4. Jefferson T, Jones MA, Doshi P, et al. “Neuraminidase inhibitors for preventing and treating influenza in adults and children.” Cochrane Database of Systematic Reviews, 2014 — the full-clinical-study-report reanalysis, and the honest measure of what oseltamivir achieves. PubMed PMID: 24718923
5. Patra JK, Das G, Bose S, et al. “Star anise (Illicium verum): chemical compounds, antiviral properties, and clinical relevance.” Phytotherapy Research, 2020. The review that collects the in-vitro antiviral work; read attentive to which findings are cell culture and which are anything more. PubMed PMID: 31997473
6. Wang GW, Hu WT, Huang BK, Qin LP. “Illicium verum: a review on its botany, traditional use, chemistry and pharmacology.” Journal of Ethnopharmacology, 2011. Includes shikimic acid content and the species' chemistry in context. PubMed PMID: 21549817
7. Analytical work on shikimic acid content and extraction from Illicium verum fruit — the quantitative basis for the “a few percent of dry weight” figure. Find on PubMed
8. Literature on the shikimate pathway and aromatic amino acid biosynthesis — why the pathway is absent in animals and why that matters here. Find on PubMed
9. Process-chemistry literature on oseltamivir synthesis from shikimic acid, including work to eliminate azide intermediates. Find on PubMed
10. In-vitro antiviral studies of Illicium verum extracts and isolated constituents. Find on PubMed
11. Studies of trans-anethole and related phenylpropanoids for antiviral activity in cell culture. Find on PubMed
12. Ize-Ludlow D, Ragone S, Bruck IS, Bernstein JN, Duchowny M, Peña BM. “Neurotoxicities in infants seen with the consumption of star anise tea.” Pediatrics, 2004. Included here because “natural flu remedy” marketing is a common route to a baby being given star anise tea. PubMed PMID: 15492355
13. Hanula R, Bortolussi-Courval E, Mendel A, Ward BJ, Lee TC, McDonald EG. “Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis.” JAMA Internal Medicine, 2024. PubMed PMID: 37306992
14. Hayden FG, Sugaya N, Hirotsu N, et al. “Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.” The New England Journal of Medicine, 2018. PubMed PMID: 30184455
15. Monto AS, Kuhlbusch K, Bernasconi C, et al. “Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.” The New England Journal of Medicine, 2025. PubMed PMID: 40267424
16. Banu MS, Suryakodi S, Saha RK, et al. “Antiviral potential of aqueous extract of star anise Illicium verum against fish nodavirus.” Diseases of Aquatic Organisms, 2025. PubMed PMID: 41195617

Connections

• All Herbs
• Star Anise (Illicium verum) — the main reference page, including the summary version of this correction.
• Star Anise Safety — the adulteration problem, and why “flu tea for the kids” is the dangerous version of this myth.
• Star Anise for Respiratory Health and Cough — the cough tradition, which is separate from and much older than the oseltamivir story.
• Influenza — the disease, its risk groups, and what antiviral treatment does and does not do.
• Bronchitis — the usual sequel to a respiratory virus, and usually not bacterial either.
• Pulmonology — the full respiratory disease index.
• Elderberry and Elderberry Benefits — the other herb marketed hard for influenza, with a genuinely different and more interesting evidence picture.
• Echinacea — the classic cold-and-flu herb, and a case study in how heterogeneous trials get summarised optimistically.
• Ginger and Ginger Benefits — a warming spice with real human trial data, if not for flu.
• Cinnamon — star anise's partner in five-spice, and the other half of a good sick-day broth.
• Schisandra — star anise's actual botanical relative in the Schisandraceae.

Disclaimer. This page is educational and is not medical advice. No research shows star anise preventing, shortening or treating influenza or any other viral infection in people, and none supports any product containing star anise or shikimic acid in place of vaccination or prescribed antiviral treatment. People with influenza symptoms who are pregnant, over 65, under 5, immunosuppressed, or living with chronic lung, heart, kidney, liver or neurological disease are the groups at higher risk of complications, and antivirals are studied as treatment started early. Breathlessness, chest pain, confusion, or symptoms that improve and then sharply worsen are signs hospitals treat as urgent. A published series describes 7 infants with neurological reactions after star anise tea, and its authors state that the tea should no longer be given to infants. Taking star anise essential oil internally is described as a hazard.

Back to Table of Contents

Featured Videos